This could result in direct effects on cancer cells through the reduction of the ADO levels present in the tumor microenvironment as well as in the re-activation of the host response by the maintenance of increased levels of ATP able to activate purinergic receptors and to recruit immune cells into the tumor. The gene discussed is ADO; the disease is cancer.